BRUIN MCL-321: A Phase 3 Open-Label, Randomised Study of Pirtobrutinib versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated, BTK Inhibitor Naive Mantle Cell Lymphoma (Trial in Progress)

Toby Eyre; Nirav Shah; Steven Le Gouill; Martin Dreyling; Elisabeth Vandenberghe; Wojciech Jurczak; Yucai Wang; Chan Cheah; Mitul Gandhi; Christopher Chay; Jeff Sharman; David Andorsky; Ming Yin; Minna Balbas; Jennifer Kherani; Michael Wang

BRUIN MCL-321: A Phase 3 Open-Label, Randomised Study of Pirtobrutinib versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated, BTK Inhibitor Naive Mantle Cell Lymphoma (Trial in Progress)

Toby Eyre, Nirav Shah, Steven Le Gouill, Martin Dreyling, Elisabeth Vandenberghe, Wojciech Jurczak, Yucai Wang, Chan Cheah, Mitul Gandhi, Christopher Chay, Jeff Sharman, David Andorsky, Ming Yin, Minna Balbas, Jennifer Kherani, Michael Wang

Internal Medicine

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Pages (from-to)	117-118
Number of pages	2
Journal	British Journal of Haematology
Volume	197
Publication status	Published - Apr 2022

Cite this

Eyre, T., Shah, N., Le Gouill, S., Dreyling, M., Vandenberghe, E., Jurczak, W., Wang, Y., Cheah, C., Gandhi, M., Chay, C., Sharman, J., Andorsky, D., Yin, M., Balbas, M., Kherani, J., & Wang, M. (2022). BRUIN MCL-321: A Phase 3 Open-Label, Randomised Study of Pirtobrutinib versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated, BTK Inhibitor Naive Mantle Cell Lymphoma (Trial in Progress). British Journal of Haematology, 197, 117-118.

@article{8951ea6adb7746f898e7c16e5cfece12,

title = "BRUIN MCL-321: A Phase 3 Open-Label, Randomised Study of Pirtobrutinib versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated, BTK Inhibitor Naive Mantle Cell Lymphoma (Trial in Progress)",

author = "Toby Eyre and Nirav Shah and {Le Gouill}, Steven and Martin Dreyling and Elisabeth Vandenberghe and Wojciech Jurczak and Yucai Wang and Chan Cheah and Mitul Gandhi and Christopher Chay and Jeff Sharman and David Andorsky and Ming Yin and Minna Balbas and Jennifer Kherani and Michael Wang",

year = "2022",

month = apr,

language = "English",

volume = "197",

pages = "117--118",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

}

Eyre, T, Shah, N, Le Gouill, S, Dreyling, M, Vandenberghe, E, Jurczak, W, Wang, Y, Cheah, C, Gandhi, M, Chay, C, Sharman, J, Andorsky, D, Yin, M, Balbas, M, Kherani, J & Wang, M 2022, 'BRUIN MCL-321: A Phase 3 Open-Label, Randomised Study of Pirtobrutinib versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated, BTK Inhibitor Naive Mantle Cell Lymphoma (Trial in Progress)', British Journal of Haematology, vol. 197, pp. 117-118.

BRUIN MCL-321: A Phase 3 Open-Label, Randomised Study of Pirtobrutinib versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated, BTK Inhibitor Naive Mantle Cell Lymphoma (Trial in Progress). / Eyre, Toby; Shah, Nirav; Le Gouill, Steven et al.
In: British Journal of Haematology, Vol. 197, 04.2022, p. 117-118.

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

TY - JOUR

T1 - BRUIN MCL-321

T2 - A Phase 3 Open-Label, Randomised Study of Pirtobrutinib versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated, BTK Inhibitor Naive Mantle Cell Lymphoma (Trial in Progress)

AU - Eyre, Toby

AU - Shah, Nirav

AU - Le Gouill, Steven

AU - Dreyling, Martin

AU - Vandenberghe, Elisabeth

AU - Jurczak, Wojciech

AU - Wang, Yucai

AU - Cheah, Chan

AU - Gandhi, Mitul

AU - Chay, Christopher

AU - Sharman, Jeff

AU - Andorsky, David

AU - Yin, Ming

AU - Balbas, Minna

AU - Kherani, Jennifer

AU - Wang, Michael

PY - 2022/4

Y1 - 2022/4

M3 - Abstract/Meeting Abstract

SN - 0007-1048

VL - 197

SP - 117

EP - 118

JO - British Journal of Haematology

JF - British Journal of Haematology

ER -